- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05576571
The Utility of Cell-free Methylation Markers in Blood for Hepatocellular Carcinoma
The Utility of Cell-free Methylation Markers in Blood for the Prognosis Prediction of Locoregional Treatment for Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The subjects of this study were patients who were diagnosed with liver cancer by physicians based on AASLD clinical criteria or pathological biopsy.
Patients are those who received radiofrequency ablation or transvascular embolization in National Taiwan University Hospital. Which excludes weakness and inability to cooperate Patients with blood test, under the condition of fully informed consent, complete blood test related tumor indicators (AFP and methylation analysis). The two data are then counted Compare.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with liver cancer by AASLD clinical criteria or pathological sections are planned to receive treatment at National Taiwan University Hospital Liver local treatment such as radiofrequency ablation or transvascular embolization.
- Be over 20 years old.
- Under the condition of informed consent, willing to sign the consent form of the subjects.
Exclusion Criteria:
- Patients who are weak and unable to cooperate with blood test.
- Kidney dysfunction, serum creatinine greater than 1.5mg/dl, it is judged that computer tomography or MRI cannot be performed Vibrate the injector.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HCC case
Patients are those who received radiofrequency ablation or transvascular embolization in National Taiwan University Hospital.
Which excludes weakness and inability to cooperate Patients with blood test, under the condition of fully informed consent, complete blood test related tumor indicators (AFP and methylation analysis).
The two data are then counted Compare.
|
methylation analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate efficacy (methylation profiling results)
Time Frame: 3 month after treatment
|
Correlation of methylation profiling results with AFP and tumor treatment response.
|
3 month after treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kai-Wen Huang, MD, PhD, Study Principal Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202009079DIPB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Serum Tumor Markers
-
Mel Shiuann-Sheng LeeNovartisCompletedFunctional Outcomes | Prevention of BMD Loss After THR | Serum Markers of Bone TurnoverTaiwan
-
Axcan PharmaCompletedSerum Levels of ALAT Transaminases | Serum Markers for Fibrosis and Hepatic InflammationFrance
-
Meir Medical CenterUnknownTumor Cells and Tumor Markers in Peritoneal CavityIsrael
-
University of AarhusUnknownInflammatory Markers | Glucose Infusion | Bone MarkersDenmark
-
National Taiwan University HospitalUnknownTo Compare the Serum Apoptosis-associated Markers Between Patients With Active TB and Patients With LTBI | To Evaluate the Efficiency of Apoptosis-associated Markers to Differentiate Potential of Active TB From LTBITaiwan
-
Utah State UniversityBUILD Dairy; Glanbia NutritionalsRecruiting
-
University Hospital, Basel, SwitzerlandMetromol SAActive, not recruitingSerum FerritinSwitzerland
-
Bispebjerg HospitalCompleted
-
Tasso Inc.Recruiting
-
Shanghai 10th People's HospitalCompleted
Clinical Trials on Met-score
-
Elcelyx Therapeutics, Inc.CompletedHealthy Subjects
-
NuBiyotaUnknownObesity, Metabolically BenignCanada
-
Dow University of Health SciencesCompletedMechanical Neck PainPakistan
-
University of ConnecticutNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol ConsumptionUnited States
-
National Jewish HealthNational Heart, Lung, and Blood Institute (NHLBI); The Miriam Hospital; National...CompletedSleep Apnea, Obstructive | Continuous Positive Airway PressureUnited States
-
Elcelyx Therapeutics, Inc.CompletedType 2 Diabetes MellitusUnited States, Puerto Rico
-
Foundation University IslamabadRecruiting
-
Triemli HospitalCompleted
-
York UniversityUniversity of ManitobaCompletedMarijuana Use | Marijuana DependenceCanada
-
Universidade Norte do ParanáWithdrawn